More News!
HOUSTON, Jun 29, 2006 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX) Dr.
Yin
Chen, CytoGenix Chief Scientific Officer; Ms. Harilyn McMicken, CytoGenix,
Laboratory Director; Dr. Cy Stein, Professor of Medicine at Albert
Einstein
School of Medicine; and Dr. John Rossi, Chairman and Professor in the
Division
of Molecular Biology, City of Hope have collaborated in a study that has
been
accepted for publication in the peer-reviewed journal Clinical Cancer
Research.
Drs. Stein and Rossi are directors of the company and members of its
scientific
advisory board.
The paper titled "The Function of Bcl-2 Protein in 518A2 Melanoma Cells In
Vivo
Differs Dramatically from its In Vitro Role" presents data from
experiments
performed on mice xenografted with human melanoma tumors and demonstrates
that
Bcl-2 protein could be an important therapeutic target in reducing or
regressing
tumors.
Dr. Cy Stein, the lead investigator, states, "This study helps to validate
the
use of the CytoGenix proprietary ssDNA technology in settings where
permanent
down-regulation of gene expression is needed, leading in this case, to
unexpected and dramatic results."
Dr. Yin Chen states, "This is a significant step forward for CytoGenix
because
it is the first time that the company's ssDNA technology has been shown to
be
effective an in vivo cancer model."
AI
